NCT03437369

Efficacy and Safety on Heart Rate Control With Ivabradine on Cardiogenic Shock

Efficacy and Safety on Heart Rate Control With Ivabradine on Cardiogenic Shock (ES-FISH)

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 22 (estimated)
• Sponsor: Hospital Universitario Ramon y Cajal · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized 1:1 blinded study that evaluate in acute left heart failure-cardiogenic shock patients if ivabradine treatment can reduce pulmonary wedge pressure, without inducing a significant or relevant reduction in cardiac output or increasing the risk of arterial hypotension and with the benefit of allowing a faster titration of heart failure drugs.

Conditions

• Cardiogenic Shock

Interventions

Type	Name	Description
DRUG	Ivabradine Oral Tablet	The target dose is 10 to 15 mg / day, administered orally in two doses
OTHER	Standard of Care treatment	The study drug will be compared with the standard of Care treatment

Timeline

• Start date: 2018-05-01
• Primary completion: 2019-10-01
• Completion: 2019-10-01
• First posted: 2018-02-19
• Last updated: 2018-02-19

Locations

1 site across 1 country: Spain

Regulatory

• FDA-regulated drug study